154 related articles for article (PubMed ID: 21735447)
1. Functional characterization of EMSY gene amplification in human cancers.
Wilkerson PM; Dedes KJ; Wetterskog D; Mackay A; Lambros MB; Mansour M; Frankum J; Lord CJ; Natrajan R; Ashworth A; Reis-Filho JS
J Pathol; 2011 Sep; 225(1):29-42. PubMed ID: 21735447
[TBL] [Abstract][Full Text] [Related]
2. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
3. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.
Cousineau I; Belmaaza A
Mol Genet Genomics; 2011 Apr; 285(4):325-40. PubMed ID: 21409565
[TBL] [Abstract][Full Text] [Related]
4. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.
Rodriguez C; Hughes-Davies L; Vallès H; Orsetti B; Cuny M; Ursule L; Kouzarides T; Theillet C
Clin Cancer Res; 2004 Sep; 10(17):5785-91. PubMed ID: 15355907
[TBL] [Abstract][Full Text] [Related]
5. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
6. The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.
Baykara O; Dalay N; Bakir B; Bulut P; Kaynak K; Buyru N
Int J Med Sci; 2017; 14(7):675-679. PubMed ID: 28824300
[No Abstract] [Full Text] [Related]
7. Clarifying the role of EMSY in DNA repair in ovarian cancer.
Kondrashova O; Scott CL
Cancer; 2019 Aug; 125(16):2720-2724. PubMed ID: 31154666
[No Abstract] [Full Text] [Related]
8. Amplification of 11q13 in ovarian carcinoma.
Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
[TBL] [Abstract][Full Text] [Related]
9. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
Hughes-Davies L; Huntsman D; Ruas M; Fuks F; Bye J; Chin SF; Milner J; Brown LA; Hsu F; Gilks B; Nielsen T; Schulzer M; Chia S; Ragaz J; Cahn A; Linger L; Ozdag H; Cattaneo E; Jordanova ES; Schuuring E; Yu DS; Venkitaraman A; Ponder B; Doherty A; Aparicio S; Bentley D; Theillet C; Ponting CP; Caldas C; Kouzarides T
Cell; 2003 Nov; 115(5):523-35. PubMed ID: 14651845
[TBL] [Abstract][Full Text] [Related]
10. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
[TBL] [Abstract][Full Text] [Related]
11. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
[TBL] [Abstract][Full Text] [Related]
12. Expression of EMSY gene in sporadic ovarian cancer.
Altinisik J; Karateke A; Coksuer H; Ulutin T; Buyru N
Mol Biol Rep; 2011 Jan; 38(1):359-63. PubMed ID: 20349280
[TBL] [Abstract][Full Text] [Related]
13. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
Clements KE; Thakar T; Nicolae CM; Liang X; Wang HG; Moldovan GL
Nucleic Acids Res; 2018 Sep; 46(17):8898-8907. PubMed ID: 30032296
[TBL] [Abstract][Full Text] [Related]
14. The function of EMSY in cancer development.
Hou J; Wang Z; Yang L; Guo X; Yang G
Tumour Biol; 2014 Jun; 35(6):5061-6. PubMed ID: 24609898
[TBL] [Abstract][Full Text] [Related]
15. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
[TBL] [Abstract][Full Text] [Related]
16. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L
Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328
[TBL] [Abstract][Full Text] [Related]
17. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
18. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas.
Madjd Z; Akbari ME; Zarnani AH; Khayamzadeh M; Kalantari E; Mojtabavi N
Asian Pac J Cancer Prev; 2014; 15(4):1783-9. PubMed ID: 24641409
[TBL] [Abstract][Full Text] [Related]
19. EMSY promoted the growth and migration of ovarian cancer cells.
Zhao X; Zhou Y; Nie M; Xian S; Chen H; Wen Y; Zhang L; Huang Y; Chen M; Wang S
Tumour Biol; 2015 Apr; 36(4):3085-92. PubMed ID: 25510665
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations of CCND1 and EMSY in breast cancers.
Kirkegaard T; Nielsen KV; Jensen LB; Campbell FM; Müller S; Tovey SM; Brown S; Cooke TG; Bartlett JM
Histopathology; 2008 May; 52(6):698-705. PubMed ID: 18393977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
